» Articles » PMID: 36798942

Autonomic Nervous System and Cardiac Neuro-signaling Pathway Modulation in Cardiovascular Disorders and Alzheimer's Disease

Overview
Journal Front Physiol
Date 2023 Feb 17
PMID 36798942
Authors
Affiliations
Soon will be listed here.
Abstract

The heart is a functional syncytium controlled by a delicate and sophisticated balance ensured by the tight coordination of its several cell subpopulations. Accordingly, cardiomyocytes together with the surrounding microenvironment participate in the heart tissue homeostasis. In the right atrium, the sinoatrial nodal cells regulate the cardiac impulse propagation through cardiomyocytes, thus ensuring the maintenance of the electric network in the heart tissue. Notably, the central nervous system (CNS) modulates the cardiac rhythm through the two limbs of the autonomic nervous system (ANS): the parasympathetic and sympathetic compartments. The autonomic nervous system exerts non-voluntary effects on different peripheral organs. The main neuromodulator of the Sympathetic Nervous System (SNS) is norepinephrine, while the principal neurotransmitter of the Parasympathetic Nervous System (PNS) is acetylcholine. Through these two main neurohormones, the ANS can gradually regulate cardiac, vascular, visceral, and glandular functions by turning on one of its two branches (adrenergic and/or cholinergic), which exert opposite effects on targeted organs. Besides these neuromodulators, the cardiac nervous system is ruled by specific neuropeptides (neurotrophic factors) that help to preserve innervation homeostasis through the myocardial layers (from epicardium to endocardium). Interestingly, the dysregulation of this neuro-signaling pathway may expose the cardiac tissue to severe disorders of different etiology and nature. Specifically, a maladaptive remodeling of the cardiac nervous system may culminate in a progressive loss of neurotrophins, thus leading to severe myocardial denervation, as observed in different cardiometabolic and neurodegenerative diseases (myocardial infarction, heart failure, Alzheimer's disease). This review analyzes the current knowledge on the pathophysiological processes involved in cardiac nervous system impairment from the perspectives of both cardiac disorders and a widely diffused and devastating neurodegenerative disorder, Alzheimer's disease, proposing a relationship between neurodegeneration, loss of neurotrophic factors, and cardiac nervous system impairment. This overview is conducive to a more comprehensive understanding of the process of cardiac neuro-signaling dysfunction, while bringing to light potential therapeutic scenarios to correct or delay the adverse cardiovascular remodeling, thus improving the cardiac prognosis and quality of life in patients with heart or neurodegenerative disorders.

Citing Articles

Remodeling of the Intracardiac Ganglia During the Development of Cardiovascular Autonomic Dysfunction in Type 2 Diabetes: Molecular Mechanisms and Therapeutics.

Evans A, Li Y Int J Mol Sci. 2024; 25(22).

PMID: 39596529 PMC: 11594459. DOI: 10.3390/ijms252212464.


Exploring the prospects, advancements, and challenges of modeling of the heart-brain axis.

Mabry S, Pavon N Front Cell Neurosci. 2024; 18:1386355.

PMID: 38766369 PMC: 11099243. DOI: 10.3389/fncel.2024.1386355.


Cardiopulmonary nerve stimulation as a novel therapy for cardiac autonomic nervous system modulation.

Salavatian S, Spinelli J, Schaefer J, Libbus I, Mahajan A, Armour J Front Neurosci. 2024; 18:1377171.

PMID: 38482139 PMC: 10933133. DOI: 10.3389/fnins.2024.1377171.


Advances in cardiac tissue engineering and heart-on-a-chip.

Kieda J, Shakeri A, Landau S, Wang E, Zhao Y, Lai B J Biomed Mater Res A. 2023; 112(4):492-511.

PMID: 37909362 PMC: 11213712. DOI: 10.1002/jbm.a.37633.


Advances in the design, generation, and application of tissue-engineered myocardial equivalents.

Bernava G, Iop L Front Bioeng Biotechnol. 2023; 11:1247572.

PMID: 37811368 PMC: 10559975. DOI: 10.3389/fbioe.2023.1247572.


References
1.
Chidsey C, Braunwald E, Morrow A, Mason D . MYOCARDIAL NOREPINEPHRINE CONCENTRATION IN MAN. EFFECTS OF RESERPINE AND OF CONGESTIVE HEART FAILURE. N Engl J Med. 1963; 269:653-8. DOI: 10.1056/NEJM196309262691302. View

2.
Kanazawa H, Ieda M, Kimura K, Arai T, Kawaguchi-Manabe H, Matsuhashi T . Heart failure causes cholinergic transdifferentiation of cardiac sympathetic nerves via gp130-signaling cytokines in rodents. J Clin Invest. 2010; 120(2):408-21. PMC: 2810079. DOI: 10.1172/JCI39778. View

3.
Kumar R, Woo M, Macey P, Fonarow G, Hamilton M, Harper R . Brain axonal and myelin evaluation in heart failure. J Neurol Sci. 2011; 307(1-2):106-13. PMC: 3150745. DOI: 10.1016/j.jns.2011.04.028. View

4.
Mahfoud F, Schlaich M, Kindermann I, Ukena C, Cremers B, Brandt M . Effect of renal sympathetic denervation on glucose metabolism in patients with resistant hypertension: a pilot study. Circulation. 2011; 123(18):1940-6. DOI: 10.1161/CIRCULATIONAHA.110.991869. View

5.
Ardell J, Andresen M, Armour J, Billman G, Chen P, Foreman R . Translational neurocardiology: preclinical models and cardioneural integrative aspects. J Physiol. 2016; 594(14):3877-909. PMC: 4945715. DOI: 10.1113/JP271869. View